AU2020213713B2 - Inositol phosphate compounds for use in increasing tissular perfusion - Google Patents

Inositol phosphate compounds for use in increasing tissular perfusion

Info

Publication number
AU2020213713B2
AU2020213713B2 AU2020213713A AU2020213713A AU2020213713B2 AU 2020213713 B2 AU2020213713 B2 AU 2020213713B2 AU 2020213713 A AU2020213713 A AU 2020213713A AU 2020213713 A AU2020213713 A AU 2020213713A AU 2020213713 B2 AU2020213713 B2 AU 2020213713B2
Authority
AU
Australia
Prior art keywords
compound
inositol
formula
subject
aspects
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2020213713A
Other languages
English (en)
Other versions
AU2020213713A1 (en
Inventor
Mohamad Firas BASSISSI
Miquel David FERRER REYNÉS
Joan PERELLÓ BESTARD
María Del Mar PÉREZ FERRER
Carolina Salcedo Roca
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Vifor International AG
Original Assignee
Vifor International AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Vifor International AG filed Critical Vifor International AG
Publication of AU2020213713A1 publication Critical patent/AU2020213713A1/en
Application granted granted Critical
Publication of AU2020213713B2 publication Critical patent/AU2020213713B2/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/06—Phosphorus compounds without P—C bonds
    • C07F9/08—Esters of oxyacids of phosphorus
    • C07F9/09—Esters of phosphoric acids
    • C07F9/117—Esters of phosphoric acids with cycloaliphatic alcohols
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/661—Phosphorus acids or esters thereof not having P—C bonds, e.g. fosfosal, dichlorvos, malathion or mevinphos
    • A61K31/6615—Compounds having two or more esterified phosphorus acid groups, e.g. inositol triphosphate, phytic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
AU2020213713A 2019-01-30 2020-01-30 Inositol phosphate compounds for use in increasing tissular perfusion Active AU2020213713B2 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
EP19382061 2019-01-30
EP19382061.0 2019-01-30
US201962913259P 2019-10-10 2019-10-10
US62/913,259 2019-10-10
PCT/ES2020/070070 WO2020157362A1 (en) 2019-01-30 2020-01-30 Inositol phosphate compounds for use in increasing tissular perfusion

Publications (2)

Publication Number Publication Date
AU2020213713A1 AU2020213713A1 (en) 2021-07-22
AU2020213713B2 true AU2020213713B2 (en) 2025-08-21

Family

ID=69770927

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2020213713A Active AU2020213713B2 (en) 2019-01-30 2020-01-30 Inositol phosphate compounds for use in increasing tissular perfusion

Country Status (11)

Country Link
US (2) US20220000889A1 (https=)
EP (1) EP3917535A1 (https=)
JP (2) JP2022521119A (https=)
KR (1) KR20210148078A (https=)
CN (1) CN113365636A (https=)
AU (1) AU2020213713B2 (https=)
BR (1) BR112021014897A2 (https=)
CA (1) CA3130735A1 (https=)
IL (1) IL285084A (https=)
MX (1) MX2021008966A (https=)
WO (1) WO2020157362A1 (https=)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3113377A1 (en) 2018-10-11 2020-04-16 Sanifit Therapeutics S.A. Inositol phosphates for the treatment of ectopic calcification
AU2021380963A1 (en) * 2020-11-20 2023-06-22 ETH Zürich Inositol hexakisphosphate analogues for treatment of calcification associated kidney diseases
WO2024047037A1 (en) 2022-08-30 2024-03-07 ETH Zürich Compositions for parenteral sustained release delivery of hydrophilic drugs

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001013933A2 (en) * 1999-08-25 2001-03-01 Gmp Companies, Inc. Agents for the enhanced oxygen delivery in mammals
WO2001024830A2 (en) * 1999-10-05 2001-04-12 Theramed, Inc. Incorporation of chemical substances into cells
WO2002010177A1 (en) * 2000-08-01 2002-02-07 Gmp Companies, Inc. Ammonium salts of inositol hexaphosphate and uses thereof
WO2002009723A2 (en) * 2000-08-01 2002-02-07 Gmp Companies, Inc. Ammonium salts of hemoglobin allosteric effectors, and uses thereof
EP2974714A1 (en) * 2013-03-15 2016-01-20 Laboratorios Sanifit, S.L. Use of derivatives with c-o-p bonds in patients with renal failure
WO2017098047A1 (en) * 2015-12-11 2017-06-15 ETH Zürich Inositol derivatives for use in pathological crystallization

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5007790A (en) 1989-04-11 1991-04-16 Depomed Systems, Inc. Sustained-release oral drug dosage form
ES2124303T3 (es) 1992-03-25 1999-02-01 Depomed Inc Formas de dosificacion de farmacos orales de liberacion retardada a base de hidroxietilcelulosa.
US5582837A (en) 1992-03-25 1996-12-10 Depomed, Inc. Alkyl-substituted cellulose-based sustained-release oral drug dosage forms
AU3290397A (en) 1996-06-10 1998-01-07 Depomed, Inc. Gastric-retentive oral controlled drug delivery system with enhanced retention properties
US5972389A (en) 1996-09-19 1999-10-26 Depomed, Inc. Gastric-retentive, oral drug dosage forms for the controlled-release of sparingly soluble drugs and insoluble matter
US6635280B2 (en) 1997-06-06 2003-10-21 Depomed, Inc. Extending the duration of drug release within the stomach during the fed mode
WO1998055107A1 (en) 1997-06-06 1998-12-10 Depomed, Inc. Gastric-retentive oral drug dosage forms for controlled release of highly soluble drugs
HK1050135A1 (zh) 1999-11-02 2003-06-13 Depomed, Inc. 用於促进将药物给予胃的饭後模式药理学诱导
DE60123384T2 (de) 2000-02-04 2007-08-02 DepoMed, Inc., Menlo Park Dosierungsform des typs "hülle und kern" mit einer wirkstofffreisetzung, die sich der nullten ordnung annähert
US6488962B1 (en) 2000-06-20 2002-12-03 Depomed, Inc. Tablet shapes to enhance gastric retention of swellable controlled-release oral dosage forms
US6451808B1 (en) 2000-10-17 2002-09-17 Depomed, Inc. Inhibition of emetic effect of metformin with 5-HT3 receptor antagonists
JP3678144B2 (ja) 2000-12-22 2005-08-03 ウシオ電機株式会社 フィルム回路基板の周辺露光装置
MXPA03011096A (es) 2001-05-29 2004-12-06 Depomed Dev Ltd Metodo para el tratamiento de la enfermedad de reflujo gastroesofagico y la saturacion acida nocturna.
US20030091630A1 (en) 2001-10-25 2003-05-15 Jenny Louie-Helm Formulation of an erodible, gastric retentive oral dosage form using in vitro disintegration test data
CA2409552A1 (en) 2001-10-25 2003-04-25 Depomed, Inc. Gastric retentive oral dosage form with restricted drug release in the lower gastrointestinal tract
TWI312285B (en) 2001-10-25 2009-07-21 Depomed Inc Methods of treatment using a gastric retained gabapentin dosage
JP2005508358A (ja) 2001-10-25 2005-03-31 デポメド・インコーポレイテッド 胃滞留型ロサルタン投与量を用いる治療方法
US6723340B2 (en) 2001-10-25 2004-04-20 Depomed, Inc. Optimal polymer mixtures for gastric retentive tablets
US6682759B2 (en) 2002-02-01 2004-01-27 Depomed, Inc. Manufacture of oral dosage forms delivering both immediate-release and sustained-release drugs
ES2232302B1 (es) 2003-11-07 2006-08-01 Universitat De Les Illes Balears Myo-inositol hexafosfato para uso topico.
ES2288126B2 (es) 2006-06-01 2009-07-06 Universitat De Les Illes Balears Utilizacion de fitato como agente inhibidor de la disolucion de cristales de sales calcicas para la prevencion o tratamiento de la osteoporosis.
ES2332636B1 (es) 2008-08-06 2011-02-10 Universitat De Les Illes Balears Composicion de liquido de dialisis.
BR112014007405B1 (pt) 2011-09-29 2021-07-13 Eth Zurich Composto, mio-inositol-pentaquisfosfato-2-peg(400) e forma farmacêutica
EP2579036A1 (en) 2011-10-06 2013-04-10 Laboratorios Sanifit, S.L. Method for the direct detection and/or quantification of at least one compound with a molecular weight of at least 200
JP6893037B2 (ja) 2015-12-11 2021-06-23 エーテーハー・チューリッヒＥＴＨ Ｚｕｒｉｃｈ Ｃ．ｄｉｆｆｉｃｉｌｅ感染のための４，６−ジ−（Ｏ−チオホスフェート）−イノシトール−１，２，３，５−テトラ−Ｏ−スルフェート

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001013933A2 (en) * 1999-08-25 2001-03-01 Gmp Companies, Inc. Agents for the enhanced oxygen delivery in mammals
WO2001024830A2 (en) * 1999-10-05 2001-04-12 Theramed, Inc. Incorporation of chemical substances into cells
WO2002010177A1 (en) * 2000-08-01 2002-02-07 Gmp Companies, Inc. Ammonium salts of inositol hexaphosphate and uses thereof
WO2002009723A2 (en) * 2000-08-01 2002-02-07 Gmp Companies, Inc. Ammonium salts of hemoglobin allosteric effectors, and uses thereof
EP2974714A1 (en) * 2013-03-15 2016-01-20 Laboratorios Sanifit, S.L. Use of derivatives with c-o-p bonds in patients with renal failure
WO2017098047A1 (en) * 2015-12-11 2017-06-15 ETH Zürich Inositol derivatives for use in pathological crystallization

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
EINCK L ET AL: UPDATE IN INTENSIVE CARE AND EMERGENCY MEDICINE, SPRINGER VERLAG, BERLIN, DE, vol. 33, 1 January 1998 (1998-01-01), pages 357 - 374, XP001023862, ISSN: 0933-6788 *
J. PERELLÓ ET AL: BRITISH JOURNAL OF CLINICAL PHARMACOLOGY., vol. 84, no. 12, 3 October 2018 (2018-10-03), GB, pages 2867 - 2876, XP055579501, ISSN: 0306-5251, DOI: 10.1111/bcp.13752 *
VANESSA BOURGEAUX ET AL: BRITISH JOURNAL OF HAEMATOLOGY, vol. 157, no. 3, 7 March 2012 (2012-03-07), GB, pages 357 - 369, XP055604356, ISSN: 0007-1048, DOI: 10.1111/j.1365-2141.2012.09077.x *
WESTERLING, D. et al. Pharmacology & Toxicology (1997) Vol.81 No.6, pages 253 to 258 *

Also Published As

Publication number Publication date
IL285084A (en) 2021-09-30
CA3130735A1 (en) 2020-08-06
JP2024175025A (ja) 2024-12-17
JP2022521119A (ja) 2022-04-06
BR112021014897A2 (pt) 2021-09-28
WO2020157362A1 (en) 2020-08-06
MX2021008966A (es) 2021-11-04
KR20210148078A (ko) 2021-12-07
US20230248749A1 (en) 2023-08-10
EP3917535A1 (en) 2021-12-08
US20220000889A1 (en) 2022-01-06
AU2020213713A1 (en) 2021-07-22
CN113365636A (zh) 2021-09-07

Similar Documents

Publication Publication Date Title
US20230248749A1 (en) Inositol phosphate compounds for use in increasing tissular perfusion
JP2016512821A (ja) ヘモグロビンの修飾のための組成物及び方法
JP7033642B2 (ja) 選択的ｓ１ｐ１レセプターアゴニストを含む薬学的合剤
US6610702B2 (en) Ammonium salts of inositol hexaphosphate, and uses thereof
AU2020381775B2 (en) Inositol phosphate compounds for use in treating, inhibiting the progression, or preventing cardiovascular calcification
PL179113B1 (pl) Kompozycja farmaceutyczna do leczenia chorób sercowo-naczyniowychi do hamowania ekspresji VCAM-1 w komórkach ludzkich PL PL PL PL
WO2015031284A1 (en) Formulations comprising wetting agents and compounds for the modulation of hemoglobin (s)
JP2008536870A (ja) 治療のためのナチュラルキラー細胞活性増強法
EP1558256B1 (en) Pyrroloquinoline quinone and a beta blocker for the treatment of ischemia or reperfusion injury
US20150265549A1 (en) Stable aqueous formulation of (e)-4-carboxystyryl-4-chlorobenzyl sulfone
KR20210104743A (ko) 4-페닐부티르산을 함유하는 노시의 치료 또는 예방제
EP4281072A1 (en) Ferroportin-inhibitors for the use in the treatment of myelodysplastic syndromes (mds)
CN103596570B (zh) 作为抗癌治疗的蛋白质靶的氧化鲨烯环化酶
RU2838908C2 (ru) Соединения инозитолфосфата для применения для увеличения тканевой перфузии
US20220031690A1 (en) Anti-neurodegenerative disease agent
HK40051461A (en) Inositol phosphate compounds for use in increasing tissular perfusion
WO2011162633A1 (ru) Мягкие катионные митохондриальные разобщители
WO2025162971A1 (en) Substituted ip5 compounds for use in the treatment, inhibition of progression, and prevention of ectopic calcification
WO2012012156A1 (en) Methods and compositions for the improvement of skeletal muscle function in a mammal
JP2023141229A (ja) 高リン血症治療用医薬用組成物
HK40066584A (zh) 用於治疗心血管钙化、抑制其进展或预防心血管钙化的肌醇磷酸酯化合物
EA043008B1 (ru) Комбинации эдаравона для лечения ишемических повреждений мозга
JPWO2006107059A1 (ja) 腎灌流障害用薬

Legal Events

Date Code Title Description
PC1 Assignment before grant (sect. 113)

Owner name: VIFOR (INTERNATIONAL) LTD.

Free format text: FORMER APPLICANT(S): SANIFIT THERAPEUTICS, S.A.

FGA Letters patent sealed or granted (standard patent)